Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why

What Happened?

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.4% in the afternoon session after the stock extended its positive momentum as the company announced its expansion into the testosterone replacement therapy market. 

The telehealth company is launching a new men's health category to tap into a large, underserved market, with an estimated 20 million U.S. men struggling with low testosterone. The new offerings will initially include compounded enclomiphene. Furthermore, Hims & Hers announced an exclusive partnership with Marius Pharmaceuticals to offer KYZATREX®, an FDA-approved oral testosterone medication, starting in 2026. This strategic move marks the company's entry into the fast-growing hormonal health sector, seen as a way to diversify its portfolio, particularly as sales from its weight-loss drugs have recently slowed. Bolstering investor confidence, analysts at BTIG reiterated a 'Buy' rating on the stock.

The shares closed the day at $55.51, up 7.2% from previous close.

Is now the time to buy Hims & Hers Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Hims & Hers Health’s shares are extremely volatile and have had 96 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 1 day ago when the stock gained 4.4% on the news that the stcok's positive momentum continued as the company announced its expansion into the testosterone replacement therapy market by launching a new category in men's health. 

Hims & Hers Health is up 120% since the beginning of the year, but at $55.40 per share, it is still trading 19.4% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health’s shares 5 years ago would now be looking at an investment worth $5,036.

Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.